Brilinta tablet
For information about (Ticagrelor), click here.

# Disclaimer
WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature.  The information provided is not a medical advice or treatment.  WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer here.

# Black Box Warning

# Overview
Brilinta tablet is a P2Y12 platelet inhibitor and platelet aggregation inhibitor drug that is FDA approved for the treatment of acute coronary syndromes (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). There is a Black Box Warning for this drug as shown here. Common adverse reactions include _______.

# Adult Indications and Dosage

## FDA-Labeled Indications and Dosage (Adult)

### Acute Coronary Syndromes
- Dosing Information

## Off-Label Use and Dosage (Adult)

### Guideline-Supported Use
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information

### NonGuideline-Supported Use
- Dosing Information
- Dosing Information
- Dosing Information

# Pediatric Indications and Dosage

## FDA-Labeled Indications and Dosage (Pediatric)
- Dosing Information
- Dosing Information

## Off-Label Use and Dosage (Pediatric)

### Guideline-Supported Use
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information

### NonGuideline-Supported Use
- Dosing Information
- Dosing Information
- Dosing Information

# Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5

# Warnings
(Description)
(Description)
(Description)

# Adverse Reactions

## Clinical Trials Experience

## Postmarketing Experience
(Description)

# Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
(Description)
(Description)
(Description)
(Description)
(Description)

# Use in Specific Populations

### Pregnancy
(Description)

### Labor and Delivery
(Description)

### Nursing Mothers
(Description)

### Pediatric Use
(Description)

### Geriatric Use
(Description)

### Gender
(Description)

### Race
(Description)

### Renal Impairment
(Description)

### Hepatic Impairment
(Description)

### Females of Reproductive Potential and Males
(Description)

### Immunocompromised Patients
(Description)

# Administration and Monitoring

### Administration
(Oral/Intravenous/etc)

### Monitoring
(Description regarding monitoring, from Warnings section)
(Description regarding monitoring, from Warnings section)
(Description regarding monitoring, from Warnings section)

# IV Compatibility

## Solution

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## Y-Site

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## Admixture

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## Syringe

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## TPN/TNA

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

# Overdosage

## Acute Overdose

### Signs and Symptoms
(Description)

### Management
(Description)

## Chronic Overdose

### Signs and Symptoms
(Description)

### Management
(Description)

# Pharmacology

## Mechanism of Action
(Description)

## Structure
(Description with picture)

## Pharmacodynamics
(Description)

## Pharmacokinetics
(Description)

## Nonclinical Toxicology
(Description)

# Clinical Studies
(Description)
(Description)
(Description)

# How Supplied
(Description)
- National Drug Code (NDC):
- Storage:
- Manufactured by:
- Distributed by:

# Images

## Drug Images
(PillBox Images)

## Package and Label Display Panel
(Package Images)
(Display Panel Images)

# Patient Information

## Patient Information from FDA
(Patient Counseling Information)

## Patient Information from NLM
(Link to patient information page)

# Precautions with Alcohol
Alcohol-Brilinta tablet interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

# Look-Alike Drug Names
- (Paired Confused Name 1a)  (Paired Confused Name 1b)
- (Paired Confused Name 2a)  (Paired Confused Name 2b)
- (Paired Confused Name 3a)  (Paired Confused Name 3b)

# Drug Shortage Status

# Price